Study of Angiostatin Genetherapy for Oral Cancer

近年来，抗血管生成肿瘤治疗因其直接的内皮靶向和无耐药性而引起了人们的极大兴趣。为了实现肿瘤的消退和休眠，需要使用抗血管生成药物。肿瘤局部抗血管生成基因治疗为实现抗血管生成物质的持续治疗性释放提供了一条潜在的途径。作为实现这一目标的一步，我们使用了与血管抑素cDNA络合的脂质体，并靶向体内的人鳞状细胞癌细胞系。局部基因转移后表达血管抑素的肿瘤细胞血管明显减少，并含有大量凋亡的肿瘤细胞。这些结果证明了脂质体衍生的血管抑素在人类口腔癌辅助治疗中的潜在用途。

Antiangiogenic tumor therapies have recently attracted intense interest because of their direct endothelial targeting and the absence of drug resistance. To achieve tumor regression and tumor dormancy, antiangiogenic agents need to be administered. Local antiangiogenic gene therapy for cancer offers a potential way to achieve sustained therapeutic release of antiangiogenic substances. As a step toward this goal, we used liposomes complexed to angiostatin cDNA and targeted to human squamous cell carcinoma cell lines in vivo. Tumor cells expressing angiostatin after local gene transfer showed markedly reduced vascularity and contained many apoptotic tumor cells. These results demonstrate the potential utility of liposome-derived angiostatin for adjuvant therapy of oral cancer in humans.